Late failure of combined recombinant hepatitis B vaccine and lamivudine in treatment of a patient with chronic hepatitis B
SOUTHERN MEDICAL JOURNAL, vol.97, no.4, pp.407-409, 2004 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 97 Issue: 4
- Publication Date: 2004
- Doi Number: 10.1097/01.smj.0000091068.87861.ba
- Journal Name: SOUTHERN MEDICAL JOURNAL
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.407-409
- Keywords: hepatitis B, lamivudine, recombinant vaccine, ANTI HBV VACCINE, IMMUNOTHERAPY, THERAPY, EFFICACY
- Ankara University Affiliated: No
Abstract
We report the first case of a woman having chronic hepatitis B treated with a combination therapy of recombinant hepatitis B vaccine and lamivudine for 18 months. The main aims of such a combined therapy were to assess whether the concomitant anti-hepatitis B virus (HBV) vaccination might prevent the emergence of a mutant HBV and lead to sustained hepatitis B e antigen seroconversion with undetectable serum HBV DNA. The data from the present case demonstrated that combination of anti-HBV vaccine and lamivudine did not eliminate viral DNA despite prolonged treatment and did not have any effect on preventing resistant-type HBV. Although the combined therapy failed to reach the therapeutic endpoints, it concerned a single and unique patient. Hepatitis B vaccine and lamivudine for HBV treatment should be further investigated in randomized controlled trials.